Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 175
   

Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Review, H2 2015’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy


  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 10
Therapeutics Development 11
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 11
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 12
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 13
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Investigation by Universities/Institutes 15
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 20
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Investigation by Universities/Institutes 22
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 23
Amarantus Bioscience Holdings, Inc. 23
AnGes MG, Inc. 24
AstraZeneca Plc 25
Bayer AG 26
Biosidus S.A. 27
Biscayne Pharmaceuticals, Inc. 28
Capricor Therapeutics, Inc. 29
Eagle Pharmaceuticals, Inc. 30
Eli Lilly and Company 31
Gilead Sciences, Inc. 32
Hemostemix Ltd 33
Human Stem Cells Institute 34
Juventas Therapeutics, Inc. 35
Lacer, S.A. 36
Lee''s Pharmaceutical Holdings Limited 37
Lonestar Heart, Inc. 38
MedImmune, LLC 39
Merck & Co., Inc. 40
Miltenyi Biotec GmbH 41
Multi Gene Vascular Systems Ltd 42
Nuo Therapeutics, Inc. 43
Pluristem Therapeutics Inc. 44
The Medicines Company 45
ViroMed Co., Ltd. 46
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
ACP-01 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ALD-201 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AMRS-001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
anacetrapib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BAY-606583 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
beperminogene perplasmid - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BIS-5409 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
bivalirudin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
bivalirudin - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
BQ-123 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
C2 ceramide - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
C6 ceramide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
cangrelor - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CAP-1002 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Cryocell - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
evacetrapib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Gemacell - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Gene Therapy to Activate VEGF for Ischemia - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
ISIS-APOARx - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
JVS-100 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
LA-419 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
MEDI-6012 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
MultiGeneGraft - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
MZ-004 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
neovasculgen - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
PLX-PAD - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Protein for Cardiovascular Diseases - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Proteins for Ischemic Heart Disease - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
ranolazine ER - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
rivaroxaban - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Small Molecule for Coronary Artery Disease - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Stem Cell Therapy for Cardiovascular Disease - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
VM-202 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
ZK-001 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates 120
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 162
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 165
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 166
Featured News & Press Releases 166
Sep 01, 2015: MATRIX Trial Results Presented at Hot Line Session of ESC Congress 2015 and Simultaneously Published in The New England Journal of Medicine 166
Sep 01, 2015: Analysis from CHAMPION PHOENIX Trial Highlight the Efficacy of Cangrelor among Patients undergoing PCI via the Radial Approach 167
Jul 23, 2015: Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing 167
Jun 22, 2015: FDA approves new antiplatelet drug used during heart procedure 168
May 20, 2015: Eagle Pharmaceuticals Submits NDA for Ready-to-Use Bivalirudin to FDA 168
Apr 15, 2015: FDA Advisory Committee Recommends Approval of The Medicines Company''s Antiplatelet Therapy Cangrelor 169
Mar 30, 2015: The Medicines Company Receives European Commission Approval for Hospital Acute Care Product : KENGREXAL 169
Mar 11, 2015: The Medicines Company Presents new data on Cangrelor at 2015 American College of Cardiology Scientific Sessions in San Diego 171
Jan 07, 2015: Interleukin Announces Collaboration with Isis Pharmaceuticals for Genetic Testing Services 172
Nov 14, 2014: The Medicines Company to Present New Data on Investigational Antiplatelet Agent Cangrelor at 2014 AHA Annual Scientific Sessions in Chicago 172
Appendix 174
Methodology 174
Coverage 174
Secondary Research 174
Primary Research 174
Expert Panel Validation 174
Contact Us 174
Disclaimer 175

List of Tables

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2015 11
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Comparative Analysis by Unknown Stage Development, H2 2015 19
Products under Development by Companies, H2 2015 20
Products under Development by Companies, H2 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2015 22
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015 23
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG, Inc., H2 2015 24
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H2 2015 25
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H2 2015 26
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biosidus S.A., H2 2015 27
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015 28
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics, Inc., H2 2015 29
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Eagle Pharmaceuticals, Inc., H2 2015 30
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Eli Lilly and Company, H2 2015 31
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H2 2015 32
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Ltd, H2 2015 33
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2015 34
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics, Inc., H2 2015 35
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H2 2015 36
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee''s Pharmaceutical Holdings Limited, H2 2015 37
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart, Inc., H2 2015 38
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune, LLC, H2 2015 39
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co., Inc., H2 2015 40
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Miltenyi Biotec GmbH, H2 2015 41
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015 42
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H2 2015 43
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pluristem Therapeutics Inc., H2 2015 44
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H2 2015 45
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co., Ltd., H2 2015 46
Assessment by Monotherapy Products, H2 2015 47
Number of Products by Stage and Target, H2 2015 49
Number of Products by Stage and Mechanism of Action, H2 2015 51
Number of Products by Stage and Route of Administration, H2 2015 53
Number of Products by Stage and Molecule Type, H2 2015 55
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H2 2015 120
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2015 162
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..1), H2 2015 163
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..2), H2 2015 164
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2015 165

List of Figures

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2015 11
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Products, H2 2015 18
Assessment by Monotherapy Products, H2 2015 47
Number of Products by Top 10 Targets, H2 2015 48
Number of Products by Stage and Top 10 Targets, H2 2015 48
Number of Products by Top 10 Mechanism of Actions, H2 2015 50
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 50
Number of Products by Top 10 Routes of Administration, H2 2015 52
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 52
Number of Products by Top 10 Molecule Types, H2 2015 54
Number of Products by Stage and Top 10 Molecule Types, H2 2015 54

Published By: Global Markets Direct
Product Code: Global Markets Direct13301


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: